A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC) Meeting Abstract

  

Authors:	Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; Friedman, K.; Neville, D.; Esteva, F.; Hudis, C.; Modi, S.
Abstract Title:	A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
Meeting Title:	38th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	76
Issue:	4 Suppl.
Meeting Dates:	2015 Dec 8-12
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2016-02-15
Language:	English
ACCESSION:	WOS:000375622400291
DOI:	10.1158/1538-7445.sabcs15-p4-14-21
PROVIDER:	wos
Notes:	Meeting Abstract: P4-14-21 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/95135